Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort - 09/08/11
, Nóra Homorodi, MD a, Èva Kristóf, MD a, Csaba Király, MD a, István F. Èdes, MD a, Andrea Facskó, MD b, Noemi Pavo c, Gottfried Sodeck, MD d, Christoph Strehblow, MD d, Serdar Farhan, MD b, Gerald Maurer, MD, FACC b, Dietmar Glogar, MD, FESC c, Hans Domanovits, MD d, Kurt Huber, MD, FESC, FACC a, István Èdes, MD aRésumé |
Background |
The aim of our prospective multicenter Clopidogrel Registry was to evaluate the efficacy and safety of a 300-mg loading dose of clopidogrel at the time of ad hoc stenting in patients with suspected coronary artery disease who were not pretreated with clopidogrel for any reason, and to compare the 30-day clinical event rates with the outcome of patients pretreated with a loading dose of clopidogrel 6 to 24 hours before stenting.
Methods |
Between March 2002 and February 2004, 4160 consecutively included patients received a 300-mg loading dose of clopidogrel immediately after (group 1, n = 2679) or 6 to 24 hours before stenting (group 2, n = 1481).
Results |
The primary end point (triple composite end point of acute myocardial infarction, all-cause death, and urgent repeat target vessel revascularization) at 30 days occurred in 4.74% versus 2.77% in groups 1 and 2, respectively (P = .002). The secondary end point events, the stent thrombosis, occurred significantly more frequently in group 1, with a trend toward increase in incidence of death, target vessel revascularization, or need for glycoprotein IIb/IIIa antagonists during percutaneous coronary intervention. Pretreatment with clopidogrel was associated with more major bleeding (secondary safety end point) (0.41% vs 1.35% in groups 1 and 2, respectively; P = .001).
Conclusions |
The results of our multicenter prospective Clopidogrel Registry demonstrate lower efficacy of a 300-mg loading dose of clopidogrel at the time of stenting compared with pretreatment 6 to 24 hours before percutaneous coronary intervention on the 30-day composite clinical end point in the large unselected patient cohort, which suggests the benefit of clopidogrel pretreatment in all incoming patients with suspected significant coronary artery disease scheduled for coronary angiography.
Le texte complet de cet article est disponible en PDF.Plan
| This work was supported by Hungarian Academy of Sciences grant T 035279 and a Hungarian Ministry of Social Welfare NKFP Project. |
Vol 153 - N° 2
P. 289-295 - février 2007 Retour au numéro
Article précédent
- Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test
- Frederick E. Dewey, James V. Freeman, Gregory Engel, Raul Oviedo, Nayana Abrol, Natasha Ahmed, Jonathan Myers, Victor F. Froelicher
- Anatomical and physiologic assessments in patients with small coronary artery disease: Final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial
- Marco A. Costa, Manel Sabate, Rodolfo Staico, Fernando Alfonso, Ana C. Seixas, Mariano Albertal, Arthur Crossman, Dominick J. Angiolillo, Martin Zenni, J. Eduardo Sousa, Carlos Macaya, Theodore A. Bass
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?